PRESENTATION OUTLINE

PART 1. NIH STEWARDSHIP OVERVIEW

• NIH STEWARDSHIP GOALS
• HUMAN SUBJECTS RESEARCH
• NIH-FUNDED CLINICAL TRIALS

PART 2. NCI CLINICAL TRIALS STEWARDSHIP ACTIVITIES

• IMPLEMENTATION & COMMUNICATION
PART 1. NATIONAL INSTITUTES OF HEALTH REFORMS AND INITIATIVES
NIH PROPOSES A “STEWARDSHIP” APPROACH
2016: NIH ANNOUNCES 1ST SERIES OF REFORMS & INITIATIVES

ADDRESSING CHALLENGES IN DESIGN, EFFICIENCY, AND REPORTING OF CLINICAL TRIALS


NIH POLICY CHANGES TO ENHANCE STEWARDSHIP

- Good Clinical Practice
- New Application Forms
- Single IRB
- Clinical Trial Review Criteria
- Clinical Trial FOAs
- Registration & Reporting
NIH POLICY CHANGES THROUGHOUT THE CLINICAL TRIAL LIFE CYCLE

Ensure Public Trust
✓ Scientific Rigor
✓ Transparency
✓ Ethical Oversight
POLICIES FOR **ALL** RESEARCH INVOLVING HUMAN PARTICIPANTS

- Use of a single Institutional Review Board (IRB) for multi-site studies
- New forms to collect human subjects information
- NEW PHS HUMAN SUBJECTS AND CLINICAL TRIAL FORM
- FORMS E APPLICATION PACKAGE
- AVAILABLE NOW
SINGLE INSTITUTIONAL REVIEW BOARD (sIRB)

NOT-OD-16-094: All domestic multi-site studies will use sIRB for ethical review required of non-exempt humans subjects research protocols

Must include a plan that describes:

- The use of a sIRB selected to serve as the IRB of record
- How communications between sites and sIRB will be handled

Standardized agreements have been developed that allow institutions to rely on a sIRB

- NCATS Streamlined, Multisite, Accelerated Resources for Trials (SMART) IRB Platform

There are exceptions...
PHS Human Subjects and Clinical Trials Information Form

- Consolidates information from multiple forms
- Incorporates structured data fields
- Collects human subjects, inclusion enrollment, and clinical trial information at the study-level (e.g., Protocol Synopsis, Statistical Plan,)
- Includes a Clinical Trials Questionnaire

Does the study…

1. Involve one or more human subjects?
2. Prospectively assign human subject(s) to intervention(s)?
3. Evaluate the effect of intervention(s) on the human subject(s)?
4. Have a health-related biomedical or behavioral outcome?

If “yes” to ALL – it’s a clinical trial

NOTE:
- Select right NIH FOA
- Write research strategy and human subjects sections
- Comply with appropriate policies
NIH POLICIES CHANGES FOR CLINICAL TRIALS

Research that Meets the NIH Definition of a Clinical Trial

- Training in Good Clinical Practice (GCP)
- Clinical trial-specific Funding Opportunity Announcements (FOAs)
- New review criteria
- Expanded registration and results reporting in ClinicalTrials.gov

Good Clinical Practice Effective Now!

Clinical Trial FOAs January 25, 2018

Trial Review Criteria January 25, 2018

Registration & Reporting Effective Now!
ICH – GOOD CLINICAL PRACTICE TRAINING

**Who:** All NIH-funded investigators and NCI staff involved in the conduct, oversight or management of clinical trials

**What:** Both are expected to receive Good Clinical Practice training

**Why:** To assure the safety, integrity, and quality of clinical trials

**How:** Through a class or course, academic training program, or certification from a recognized clinical research professional organization (NIAID, NIDA, and CITI courses available)
Clinical Trial-Specific Funding Opportunity Announcements

NOT-OD-16-147: All clinical trial applications **MUST** be submitted to an FOA that allows clinical trials

- Clinical Trial - Not Allowed
- Clinical Trial - Optional
- Clinical Trial – Required
- No Independent Clinical Trial – K grants
REVIEW CRITERIA FOR CLINICAL TRIALS

NOT-OD-17-118: FOAs that accept clinical trials will include new review criteria

**Scored Review Criteria**
- ✓ Significance
- ✓ Investigator
- ✓ Innovation
- ✓ Approach
- ✓ Environment

**Additional Review Criteria**
- ✓ Study Timeline
Dissemination of NIH-Funded Clinical Trial Information
NOT-OD-16-149

Who: All investigators conducting clinical trials funded in whole or in part by the NIH regardless of trial phase

What: Sponsors need to register* and report results** of trials in ClinicalTrials.gov

Why: Increase the availability of information about clinical trials and their results to the public in a timely manner

*within 21 days of 1st patient enrollment
**no later than 1 year after trial’s primary completion date
PART 2. NATIONAL CANCER INSTITUTE’S STEWARDSHIP ACTIVITIES
NCI STEWARDSHIP GOAL

In 2016, NCI launched an institute-wide effort to achieve:

“Effective oversight and management across multiple NCI Divisions, Offices, and Centers for ensuring quality of the clinical trial, safety of research participants, reliability of data, and appropriate stewardship of funds.”
IMPLEMENTATION PLANNING GROUPS & ACTIVITIES
(Help to work through implementation)

NIH CLINICAL TRIALS OPERATION WORK GROUP (CTOW)
- Central point of contact and communication for NIH Policies
- Help OER work through implementation issues (e.g., Training on FOA writing)

NCI’S CLINICAL TRIALS STEWARDSHIP COMMITTEE (NCTSC)
- Consists of representatives across NCI
- Guides the development of NCI’s specific Clinical Trials Stewardship Initiative
- Creates a unified set of Standard Operating Procedures for oversight

NCI’S OFFICE OF COMMUNICATION AND PUBLIC LIAISON (OCPL)
- Tracking and communicating NIH updates to NCI staff
- Outreach to the oncology scientific community
- Establishing new employee orientation materials
CRUCIAL 1st STEP: DEVELOPING NCI-SPECIFIC FOAS
(34 Clinical Trial Allowed FOAs)

NCI IS NOT PARTICIPATING IN NIH CLINICAL TRIAL-
REQUIRED PARENT R01 & R21

<table>
<thead>
<tr>
<th>FOA</th>
<th>NCI-Specific CLINICAL TRIAL (CT) FOA</th>
</tr>
</thead>
<tbody>
<tr>
<td>New Investigator-initiated Clinical Trials (R01)</td>
<td>Yes: CT Required</td>
</tr>
<tr>
<td></td>
<td>DCTD &amp; DCCPS-DCP</td>
</tr>
<tr>
<td>NCI Clinical and Translational Exploratory/Developmental Studies (R21)</td>
<td>Yes: Reissue as CT Optional</td>
</tr>
<tr>
<td>NCI Small Grants Program for Cancer Research (R03)</td>
<td>Yes: Reissue as CT Optional</td>
</tr>
<tr>
<td>NCI Program Project Applications (P01)</td>
<td>Yes: Reissue as CT Optional</td>
</tr>
<tr>
<td>NCI Specialized Programs of Research Excellence (P50)</td>
<td>Yes: Reissue as CT Required</td>
</tr>
</tbody>
</table>
NCTSC NEXT STEP: BETA TESTING TOOLS USED BY NCI STAFF TO MONITOR NCI-FUNDED TRIALS

FOCUS: UNIFYING PROGRAM OFFICER AND GRANTS MANAGEMENT REVIEWS OF PROGRESS REPORTS:

METHOD: Utilizes a risk-based approach to review and monitoring of trials

PROCEDURE:
1. Identify resource risk elements associated with the intervention, study design, trial features, readiness for activation, etc.
2. Resource risk classification determines the frequency in reporting progress to NCI
3. Create a Clinical Trial Management Plan based on resource risk classification
OCPL EFFORTS: DEVELOPING RESOURCES FOR RESEARCHERS

<table>
<thead>
<tr>
<th>August 11, 2017</th>
<th>Mid-November 2017</th>
</tr>
</thead>
<tbody>
<tr>
<td>• NIH OER notified all grantees by email</td>
<td>• NCI Divisions, Offices and Centers will notify NCI grantees by email along with the broader community (advocates and other organizations)</td>
</tr>
<tr>
<td>• Provided web page resource: <a href="https://grants.nih.gov/policy/clinical-trials.htm">Clinical Trial Requirements for NIH Grantees and Contractors web page</a></td>
<td>• Will provide an NCI-specific web page resource</td>
</tr>
<tr>
<td>• NIH resource for more info: <a href="https://grants.nih.gov/policy/clinical-trials.htm">https://grants.nih.gov/policy/clinical-trials.htm</a></td>
<td>• Grantees can contact their PDs, etc.</td>
</tr>
</tbody>
</table>
ADDITIONAL MATERIALS
KEY DATES TO REMEMBER

- **October 25, 2017**: FORMS-E application packages available for new clinical trial-specific FOAs due.
- **November 5, 2017**: New clinical trial-specific FOAs available.
- **January 25, 2018**: First due date for new FORMS-E application.

New Clinical Trial Procedures at NCI
ACKNOWLEDGEMENT

NCI CLINICAL TRIALS STEWARDSHIP COMMITTEE

DCCPS: Stephanie Land, Kathleen Castro, Wynne Norton
DCP: Ann O’Mara, Linda Parreco, Leslie Ford
DCTD: Roy Wu, Vikram Devgan, Jan Casadei, James Zwiebel, Peter Ujhazy, Rosemary Wong, Dan Xi, Mostafa Nokta, Rebecca Huppi, Eileen Resnick, Karen Said
DEA: Chris Hatch, Shamala Srinivas
CCCT: LeeAnn Jensen, Gisele Sarosy
GMO: Crystal Wolfrey
SBIR/STTR: Andrew Kurtz
OA: Marla Jacobson, Donna Perry-Lalley, MaryAnne Golling
OCPL: Rhonda DeJoice, LaTonya Kittles, Kelly Lawhead, Sara Johnson
Emmes: Chris Williams
THANK YOU FOR YOUR ATTENTION

Questions?